NEW YORK, NY / ACCESSWIRE / May 14, 2021 /Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. For more details and to speak with our firm without cost or obligation, follow the links below.
SOS Limited (NYSE:SOS)
CONTACT JAKUBOWITZ ABOUT SOS:
https://claimyourloss.com/securities/sos-limited-loss-submission-form/?id=15872&from=1
Class Period : July 22, 2020 - February 25, 2021
Lead Plaintiff Deadline : June 1, 2021
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) SOS had misrepresented the true nature, location, and/or existence of at least one of the principal executive offices listed in its SEC filings; (ii) HY and FXK were either undisclosed related parties and/or entities fabricated by the Company; (iii) the Company had misrepresented the type and/or existence of the mining rigs that it claimed to have purchased; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
Repro Med Systems, Inc. (NASDAQ:KRMD)
CONTACT JAKUBOWITZ ABOUT KRMD:
https://claimyourloss.com/securities/repro-med-systems-inc-loss-submission-form/?id=15872&from=1
Class Period : August 4, 2020 - January 25, 2021
Lead Plaintiff Deadline : May 25, 2021
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) starting in January 2020, Repro Med Systems ramped up the use of allowances, including growth rebates, to retain key customers and to incentivize growth; (2) as the rebates accrued, the Company's net sales were reasonably likely to decline; and (3) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Acadia Pharmaceuticals Inc. (NASDAQ:ACAD)
CONTACT JAKUBOWITZ ABOUT ACAD:
https://claimyourloss.com/securities/acadia-pharmaceuticals-inc-loss-submission-form/?id=15872&from=1
Class Period : June 15, 2020 - April 4, 2021
Lead Plaintiff Deadline : June 18, 2021
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) the materials submitted in support of the pimavanserin sNDA contained statistical and design deficiencies; (ii) accordingly, the pimavanserin sNDA lacked the evidentiary support that the Company had led investors to believe it possessed; (iii) the FDA was unlikely to approve the pimavanserin sNDA in its present form; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (212) 867-4490
F: (212) 537-5887
SOURCE: Jakubowitz Law